Jump to content

Mitizodone

Add links
From Wikipedia, the free encyclopedia
Mitizodone
Clinical data
Other namesHEC-113995; HEC113995
Routes of
administration		Oral[1][2]
Drug classSerotonin reuptake inhibitor; Serotonin 5-HT1A receptor partial agonist

Mitizodone (developmental code name HEC-113995) is a serotonin reuptake inhibitor and serotonin 5-HT1A receptor partial agonist which is under development for the treatment of major depressive disorder.[1][3][4][2][5] It is being developed by Sunshine Lake Pharma and is being developed towards approval specifically in China.[1][3][4] As of April 2023, no recent development of mitizodone has been reported.[1] The drug has reached phase 3 clinical trials.[1][3][4] Its chemical structure does not yet appear to have been disclosed.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "Mitizodone phosphate". AdisInsight. 28 April 2023. Retrieved 1 March 2025.
  2. ^ a b IsHak WW, Meyer A, Freire L, Totlani J, Murphy N, Renteria S, Salem M, Chang T, Abdelsalam R, Khan R, Chandy T, Parrish T, Hirsch D, Patel B, Steiner AJ, Kim S, Hedrick R, Pechnick RN, Danovitch I (2024). "Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review". Innov Clin Neurosci. 21 (7–9): 27–47. PMC 11424068. PMID 39329027.
  3. ^ a b c "Delving into the Latest Updates on Mitizodone Phosphate with Synapse". Synapse. 23 January 2025. Retrieved 1 March 2025.
  4. ^ a b c "Mitizodone phosphate Drug Profile". Ozmosi. 15 October 2021. Retrieved 1 March 2025.
  5. ^ Singh MK, Thase ME (February 2025). "Current Progress in Targeted Pharmacotherapy to Treat Symptoms of Major Depressive Disorder: Moving From Broad-Spectrum Treatments to Precision Psychiatry". CNS Spectr: 1–45. doi:10.1017/S1092852925000094. PMID 39915247.



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mitizodone&oldid=1278390253"